Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05176665
Other study ID # EMB01X201
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date October 21, 2021
Est. completion date August 31, 2024

Study information

Verified date June 2023
Source Shanghai EpimAb Biotherapeutics Co., Ltd.
Contact Xiaodong Sun, MD
Phone +86-21-61043299
Email CT.info@epimab.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is to evaluate the safety and antitumor activity of EMB-01 in advanced/metastatic gastrointestinal cancers, including gastric cancer, hepatocellular cancer, cholangiocarcinoma and colorectal cancer.


Description:

This is an open-label, Phase Ib/II, multi-stage study of EMB-01 in patients with advanced gastrointestinal tumors including gastric cancer, hepatocellular cancer, cholangiocarcinoma cancer and colorectal cancer, who have EGFR/cMET gene alterations or protein over expression and progressed on available standard therapies and for whom no standard therapy exists that would confer clinical benefit. All patients will be prescreened for cMET and EGFR genetic alterations and protein expression. Only those who met the molecular pre-screening criteria will proceed to clinical screening to determine the eligibility. The study will consist of Phase Ib part and Phase II part, both phases will consist of a molecular prescreening period, screening period, treatment period, safety follow-up period, and disease progression follow-up.


Recruitment information / eligibility

Status Recruiting
Enrollment 152
Est. completion date August 31, 2024
Est. primary completion date August 4, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: Molecular Pre-screening Inclusion criteria (Phase II only) 1. cMET amplification in tumor sample; OR 2. cMET overexpression in tumor sample; OR 3. EGFR overexpression in tumor sample; OR 4. Other EGFR or cMET gene alteration in blood sample (circulating tumor DNA, ctDNA). In Phase II, CRC patients must provide blood sample for NGS test, but may not provide tumor samples at prescreening visit. CRC patients don't need to meet the above criteria of EGFR/cMET amplification, overexpression or gene aberration. Screening Inclusion Criteria 1. Able to understand and willing to sign the Informed Consent Form (ICF). 2. Histologically/cytologically confirmed advanced/metastatic gastric cancer, HCC, BTC, and colorectal cancer with measurable disease (RECIST V1.1). To be eligible, patients must meet following criteria: 1. Have failed all standard of care therapies known to confer clinical benefit. Patients who is not tolerable on standard of care therapies, or no standard of care therapies available, or refused standard of care therapies are eligible. 2. Have measurable disease as defined by RESIST v 1.1. 3. Archival tumor tissue (formalin-fixed or paraffin-embedded, collected within 1 year) or a new biopsy collected in the molecular pre-screening visit. 4. Must have adequate organ function. 5. Regarding prior anti-tumor therapy: 1. Patients who have received any anticancer drugs approved or investigational, including chemotherapy, immune therapy, hormonal therapy (Exceptions: hormone-replacement therapy, testosterone or oral contraceptives), biologic therapy, must have stopped treatment at least 4 weeks or within 5 half -lives whichever shorter before first dose of EMB-01. 2. Local radiotherapy or radiation therapy for bone metastases must have stopped 2 weeks before first dose of EMB-01. No therapeutic radiopharmaceuticals are taken within 8 weeks before first dose of EMB-01. 3. Patients who have received prior targeted therapies must have stopped treatment for at least 4 weeks or within 5 half-lives, whichever is shorter before first dose of EMB-01. 6. Female patient with fertility or male patient whose partner has fertility should use one or more contraceptive methods for contraception starting from screening period and continue throughout the study treatment and for 3 months. 7. ECOG score =1. Exclusion Criteria: Molecular Pre-screening Exclusion Criteria Subject who meets any of the following criteria can't be proceeded to clinical screening: 1. Patients who are unwilling to sign the molecular pre-screening ICF. 2. Patients for whom the results of central laboratory testing do not meet the molecular pre-screening inclusion criteria. 3. Patients with a documented gene alteration including but not limited to HER2, KRAS, NRAS, BRAF, NTRK, ALK, RET, ROS1, and FGFR, etc. that is known to confer resistance to EGFR and/or cMET inhibitors.* * In Phase II, CRC patients with activated KRAS, NRAS or BRAF mutation should be excluded, but patients with other gene alterations do not need to be excluded. Screening Exclusion Criteria 1. Life expectancy < 3 months. 2. Patients with primary central nervous system (CNS) malignancy or symptomatic CNS (leptomeningeal or brain) metastases are not allowed. Patients with asymptomatic CNS metastases are eligible. 3. Pregnant or nursing females. 4. Patients who have had major surgery within the 28 days from the screening. Surgical wounds must be completely healed. 5. Any other serious underlying medical (e.g. uncontrolled diabetes mellitus, active uncontrolled infection, active gastric ulcer, uncontrolled seizures, cerebrovascular incidents, gastrointestinal bleeding, severe signs and symptoms of coagulation and clotting disorders, cardiac conditions), psychiatric, psychological, familial or geographical condition that, in the judgment of the investigator, may interfere with the planned staging, treatment and follow-up, affect patient compliance or place the patient at high risk from treatment-related complications.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
EMB-01
EMB-01 at the RP2D of 1600 mg will be administered as an IV infusion once weekly (QW) throughout the study. One cycle is defined as 4 weeks (4 doses). All patients will be premedicated with a histamine-1 (H1) receptor antagonist diphenhydramine (25 or 50 mg) intravenously 30-60 minutes prior to dosing in the first two cycles. Premedication for subsequent treatment cycles will depend on whether the patient develops infusion-related reactions (IRR), at the discretion of the investigator.

Locations

Country Name City State
China Beijing cancer Hospital Beijing Beijing
China Hunan Cancer Hospital Changsha
China West China Hospital, Sichuan University Chengdu
China Nanfang Hospital Guangzhou Guangdong
China The Sixth Affiliated Hospital of Sun Yat-Sen University Guangzhou
China Sir Run Run Shaw Hospital, Zhejiang University School of Medicine Hangzhou
China Harbin Medical University Cancer Hospital Harbin
China Shandong Cancer Hospital Jinan
China Gansu Provincial Hospital Lanzhou
China The Affiliated hospital of Qingdao University Qingdao
China Fudan University Shanghai Cancer Center Shanghai
China The First Affiliated Hospital of Xi'an Jiaotong University Xi'an
China First Affiliated Hospital of Zhengzhou University Zhengzhou
United States MD Anderson Cancer Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Shanghai EpimAb Biotherapeutics Co., Ltd. Labcorp Corporation of America Holdings, Inc

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 Phase 1b, screening up to follow-up (30 days after the last dose)
Primary Best Overall Response (BOR) as assessed by RECIST v1.1 Best Overall Response (BOR) as assessed by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Primary Objective Response Rate (ORR) as assessed by RECIST v1.1 Objective Response Rate (ORR) as assessed by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Primary Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Primary Disease Control Rate (DCR) as assess by RECIST v1.1 Disease Control Rate (DCR) as assess by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Primary Progression-Free Survival (PFS) as assess by RECIST v1.1 Progression-Free Survival (PFS) as assess by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Primary Maximum serum concentration (Cmax) of EMB-01 Maximum serum concentration (Cmax) of EMB-01 Phase Ib only, up to 3 months after first study drug administration
Primary Trough serum concentration (Ctrough) of EMB-01 Trough serum concentration (Ctrough) of EMB-01 Phase Ib only, predose, through treatment completion, an average of 1 year
Primary Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t) Area under the concentration-time curve from time 0 (pre-dose) to the time of the dosing interval (AUC0-t) Phase Ib only, up to 3 months after first study drug administration
Primary Area under the concentration-time curve from time 0 to infinity (AUC0-inf) Area under the concentration-time curve from time 0 to infinity (AUC0-inf) Phase Ib only, up to 3 months after first study drug administration
Primary Elimination half-life (T1/2) Elimination half-life (T1/2) Phase Ib only, up to 3 months after first study drug administration
Primary Systemic clearance (CL) Systemic clearance (CL) Phase Ib only, up to 3 months after first study drug administration
Primary Apparent volume of distribution at steady-state (Vss) Apparent volume of distribution at steady-state (Vss) Phase Ib only, up to 3 months after first study drug administration
Primary Accumulation Ratio (AR) after multiple dosing Accumulation Ratio (AR) after multiple dosing Phase Ib only, up to 3 months after first study drug administration
Primary Incidence of positive ADA Incidence of positive ADA Phase Ib only, up to the 30-day safety follow-up visit after EOT
Primary Clinical benefit rate(CBR) as assess by RECIST v1.1 Clinical benefit rate(CBR) as assess by RECIST v1.1 Phase II, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 Number of participants with Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 Phase II, screening up to follow-up (30 days after the last dose)
Secondary Maximum serum concentration (Cmax) of EMB-01 Maximum serum concentration (Cmax) of EMB-01 Phase II, up to 3 months after first study drug administration
Secondary Trough serum concentration (Ctrough) of EMB-01 Trough serum concentration (Ctrough) of EMB-01 Phase II, predose, through treatment completion, an average of 1 year
Secondary Incidence of positive ADA Incidence of positive ADA Phase II , up to the 30-day safety follow-up visit after EOT
Secondary Best Overall Response (BOR) as assessed by RECIST v1.1 Best Overall Response (BOR) as assessed by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Objective Response Rate (ORR) as assessed by RECIST v1.1 Objective Response Rate (ORR) as assessed by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 Duration of Response (DoR) as assess by RECIST v1.1 as assess by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Disease Control Rate (DCR) as assess by RECIST v1.1 Disease Control Rate (DCR) as assess by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Progression-Free Survival (PFS) as assess by RECIST v1.1 Progression-Free Survival (PFS) as assess by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
Secondary Clinical benefit rate(CBR) as assess by RECIST v1.1 Clinical benefit rate(CBR) as assess by RECIST v1.1 Phase Ib, from the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months
See also
  Status Clinical Trial Phase
Completed NCT03826043 - THrombo-Embolic Event in Onco-hematology N/A
Terminated NCT03166631 - A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread Phase 1
Completed NCT01938846 - BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors Phase 1
Recruiting NCT06058312 - Individual Food Preferences for the Mediterranean Diet in Cancer Patients N/A
Completed NCT03308942 - Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants Phase 2
Recruiting NCT06018311 - Exercising Together for Hispanic Prostate Cancer Survivor-Caregiver Dyads N/A
Withdrawn NCT05431439 - Omics of Cancer: OncoGenomics
Completed NCT01343043 - A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma Phase 1
Completed NCT01938638 - Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Phase 1
Recruiting NCT05514444 - Study of MK-4464 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced/Metastatic Solid Tumors (MK-4464-001) Phase 1
Recruiting NCT02292641 - Beyond TME Origins N/A
Terminated NCT00954512 - Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004) Phase 1/Phase 2
Recruiting NCT04958239 - A Study to Test Different Doses of BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) Phase 1
Recruiting NCT04627376 - Multimodal Program for Cancer Related Cachexia Prevention N/A
Completed NCT01222728 - Using Positron Emission Tomography to Predict Intracranial Tumor Growth in Neurofibromatosis Type II Patients
Recruiting NCT06004440 - Real World Registry for Use of the Ion Endoluminal System
Active, not recruiting NCT05636696 - COMPANION: A Couple Intervention Targeting Cancer-related Fatigue N/A
Not yet recruiting NCT06035549 - Resilience in East Asian Immigrants for Advance Care Planning Discussions N/A
Recruiting NCT06004466 - Noninvasive Internal Jugular Venous Oximetry
Completed NCT02909348 - Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab